Spero Therapeutics (SPRO) Stock Price, News & Analysis

Company Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.81 to $0.84
• 50-Day Range: $0.75 to $1.10
• 52-Week Range: $0.74 to $1.89
• Volume: 82,071 shs
• Average Volume: 216,602 shs
• Market Capitalization: $45.31 million
• P/E Ratio: 11.87
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Spero Therapeutics Stock Analysis - MarketRank™

Spero Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 144th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Spero Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spero Therapeutics is 11.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spero Therapeutics is 11.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.70.

Price to Book Value per Share Ratio

Spero Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.69% of the outstanding shares of Spero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Spero Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spero Therapeutics has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spero Therapeutics does not currently pay a dividend.

Dividend Growth

Spero Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.80

Percentage of Shares Shorted

0.69% of the outstanding shares of Spero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Spero Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spero Therapeutics has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,288.00 in company stock.

Percentage Held by Insiders

Only 4.52% of the stock of Spero Therapeutics is held by insiders.

Percentage Held by Institutions

Only 25.60% of the stock of Spero Therapeutics is held by institutions.

SPRO Stock Analysis - Frequently Asked Questions

How have SPRO shares performed this year?

Spero Therapeutics' stock was trading at $1.03 at the beginning of 2025. Since then, SPRO stock has decreased by 19.3% and is now trading at $0.8310.
View the best growth stocks for 2025 here.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Monday, August, 5th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The firm earned $10.20 million during the quarter, compared to analyst estimates of $9.80 million. Spero Therapeutics had a trailing twelve-month return on equity of 4.03% and a net margin of 3.30%.

When did Spero Therapeutics IPO?

Spero Therapeutics (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Spero Therapeutics' major shareholders?

Top institutional shareholders of Spero Therapeutics include Anson Funds Management LP (7.04%), Renaissance Technologies LLC (2.03%), ADAR1 Capital Management LLC (1.47%) and Monimus Capital Management LP (0.57%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRO
• CUSIP: N/A
• CIK: 1701108
• Web: sperotherapeutics.com
• Phone: (857) 242-1600
• Fax: N/A
• Employees: 150
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +501.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.07
• Trailing P/E Ratio: 11.87
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $22.81 million
• Net Margins: 3.30%
• Pretax Margin: 3.39%
• Return on Equity: 4.03%
• Return on Assets: 2.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.68
• Quick Ratio: 2.68

Sales & Book Value

• Annual Sales: $103.78 million
• Price / Sales: 0.44
• Cash Flow: $0.51 per share
• Price / Cash Flow: 1.62
• Book Value: $2.02 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 54,520,000
• Free Float: 52,054,000
• Market Cap: $45.31 million
• Optionable: Optionable
• Beta: 0.61